Showing 1 - 20 results of 350 for search '"Безопасность и риск фармакотерапии"', query time: 0.14s Refine Results
  1. 1
    Drug Safety Monitoring Information

    Drug Safety Monitoring Information by E. V. Shubnikova, E. O. Zhuravleva, N. Yu. Velts, P. M. Giulakhmedova, A. A. Druzhinina

    Published 2021-07-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  2. 2
    Comparative Preclinical Evaluation of the Safety, Antifungal Activity, and Pharmacokinetics of Sertaconazole Products for External Use

    Comparative Preclinical Evaluation of the Safety, Antifungal Activity, and Pharmacokinetics of Sertaconazole Products for External Use by V. M. Kosman, M. V. Karlina, V. A. Vavilova, K. E. Borovkova, K. L. Kryshen, N. V. Marchenko, S. A. Kopatko, I. V. Sychkova, D. R. Kargopoltseva, M. N. Makarova, V. G. Makarov

    Published 2024-04-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  3. 3
    ADVERSE DRUG REACTIONS IN CRIMEA REPUBLIC IN 2013

    ADVERSE DRUG REACTIONS IN CRIMEA REPUBLIC IN 2013 by O. I. Koniaieva, O. V. Matvieiev

    Published 2022-06-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  4. 4
    Russian CIOMS-form

    Russian CIOMS-form by Editorial Article

    Published 2018-02-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  5. 5
    Safety of COVID-19 vaccines

    Safety of COVID-19 vaccines by B. K. Romanov

    Published 2022-12-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  6. 6
    Antibiotics for the treatment of COVID‐19

    Antibiotics for the treatment of COVID‐19 by article Editorial

    Published 2022-07-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  7. 7
    Idiosyncratic Drug-Induced Liver Injury: From Pathogenesis to Risk Reduction

    Idiosyncratic Drug-Induced Liver Injury: From Pathogenesis to Risk Reduction by I. A. Mazerkina

    Published 2023-06-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  8. 8
    Analysis of Noncompliances with Legislative Requirements in Pharmacovigilance Materials of Registration Dossiers

    Analysis of Noncompliances with Legislative Requirements in Pharmacovigilance Materials of Registration Dossiers by E. O. Zhuravleva, N. Yu. Velts, G. V. Kutekhova

    Published 2021-12-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  9. 9
    Risk Management Plan: Expert Review of Applications for Marketing Authorisation in the EAEU Depending on the Type of Medicinal Product (Review)

    Risk Management Plan: Expert Review of Applications for Marketing Authorisation in the EAEU Depending on the Type of Medicinal Product (Review) by T. M. Bukatina, E. V. Shubnikova

    Published 2024-07-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  10. 10
    Erratum: Velts N.Yu. et al. Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors

    Erratum: Velts N.Yu. et al. Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Req... by Article Editorial

    Published 2024-12-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  11. 11
    Susceptibility of HEK293 and RPTEC Cell Lines to Nephrotoxic Effects of Cefuroxime and Cefepime: A Comparative Study

    Susceptibility of HEK293 and RPTEC Cell Lines to Nephrotoxic Effects of Cefuroxime and Cefepime: A Comparative Study by V. A. Evteev, I. S. Semenova, N. D. Bunyatyan, A. B. Prokofiev

    Published 2023-06-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  12. 12
    Retrospective Analysis of Spontaneous Reports of Fatal Adverse Reactions Associated with Lidocaine

    Retrospective Analysis of Spontaneous Reports of Fatal Adverse Reactions Associated with Lidocaine by A. V. Matveev, E. I. Konyaeva, E. A. Egorova, A. M. Beitullaev

    Published 2024-04-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  13. 13
    Improving Healthcare Professionals’ Reporting of Adverse Drug Reactions and Medication Errors

    Improving Healthcare Professionals’ Reporting of Adverse Drug Reactions and Medication Errors by Article Editorial

    Published 2024-12-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  14. 14
    Analysis of Pharmacokinetic Parameters of Acetylsalicylic Acid for Prediction of Potential Nephrotoxic Effects

    Analysis of Pharmacokinetic Parameters of Acetylsalicylic Acid for Prediction of Potential Nephrotoxic Effects by L. M. Krasnykh, O. A. Goroshko, G. F. Vasilenko, G. I. Gorodetskaya, V. V. Smirnov, T. A. Rodina

    Published 2021-12-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  15. 15
    Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin

    Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin by A. A. Kachanova, Yu. A. Pimenova, G. N. Shuev, K. A. Akmalova, Zh. A. Sozaeva, N. M. Krasnova, E. A. Grishina, D. A. Sychev

    Published 2021-03-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  16. 16
    SUGGESTIONS FOR PREVENTING UNDESIRED REACTIONS AT APPLICATION IMMUNOBIOLOGICAL MEDICINAL PRODUCTS IN THE RUSSIAN FEDERATION

    SUGGESTIONS FOR PREVENTING UNDESIRED REACTIONS AT APPLICATION IMMUNOBIOLOGICAL MEDICINAL PRODUCTS IN THE RUSSIAN FEDERATION by N. A. Ozeretskovsky, K. E. Zatolochina, I. I. Snegireva

    Published 2018-02-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  17. 17
    Foreign regulatory recommendations

    Foreign regulatory recommendations by E. Y. Pasternak

    Published 2018-02-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  18. 18
    Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice

    Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice by R. N. Alyautdin, B. K. Romanov, В. К. Лепахин, N. D. Bunyatyan, V. A. Merkulov, A. N. Mironov

    Published 2022-06-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  19. 19
    Safety of Use of Russian Biosimilars of Interferon Beta-1b in the Treatment of Multiple Sclerosis: a Meta-analysis of Original Studies

    Safety of Use of Russian Biosimilars of Interferon Beta-1b in the Treatment of Multiple Sclerosis: a Meta-analysis of Original Studies by D. O. Gudz, A. E. Krasnov, R. N. Mamleev, R. K. Kagirov, M. L. Maximov

    Published 2019-06-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article
  20. 20
    Assessment of Pharmacovigilance Reporting in Russia

    Assessment of Pharmacovigilance Reporting in Russia by Yu. V. Olefir, B. K. Romanov, R. N. Alyautdin, V. K. Lepakhin, A. E. Krasheninnikov, E. V. Shubnikova

    Published 2018-12-01
    “…Безопасность и риск фармакотерапии…”
    Get full text
    Article

Search Tools: